Extracorporeal cardiac shock wave therapy for ischemic heart disease |
| |
Authors: | Hiroaki Shimokawa Kenta Ito Yoshihiro Fukumoto Satoshi Yasuda |
| |
Institution: | (1) Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryomachi, Aoba-ku, Sendai 980-8574, Japan |
| |
Abstract: | Prognosis of severe ischemic heart disease with no indication of percutaneous coronary intervention or coronary artery bypass
grafting still remains poor. Extracorporeal shock wave therapy was introduced for medical therapy more than 20 years ago to
break up kidney stones. We have demonstrated that extracorporeal cardiac shock wave therapy at a low level of ~10% of energy
density that used for urinary lithotripsy treatment, effectively induces coronary angiogenesis and improves myocardial ischemia
in a porcine model of chronic myocardial ischemia in vivo. On the basis of the promising results in animal studies, we have
recently developed a new, non-invasive angiogenic therapy with low-energy shock waves for ischemic heart disease. Our extracorporeal
cardiac shock wave therapy improved symptoms and myocardial ischemia in patients with severe coronary artery disease. These
beneficial effects of the shock wave therapy persisted for at least 12 months. Importantly, no procedural complications or
adverse effects were noted. These results indicate that our extracorporeal cardiac shock wave therapy is an effective and
non-invasive treatment for ischemic heart disease. To further confirm the usefulness and safety of our SW therapy, we are
currently conducting the second clinical trial in a randomized and placebo-controlled manner.
|
| |
Keywords: | Cardiac shock wave therapy Angiogenesis Ischemic heart disease Myocardial ischemia Growth factors |
本文献已被 SpringerLink 等数据库收录! |
|